Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CES2 | O00748 | 4/20 | 0.46 |
| ▸ | CES1 | P23141 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968821 | 1.00 | ALDH1A1 (0.61) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL19663921 | 1.00 | ALDH1A1 (0.61) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL16613214 | 0.88 | NPC1 (0.49) | ALDH1A1MAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL18017521 | 0.87 | CES2 (0.48) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7991675 | 0.87 | CES2 (0.48) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7991679 | 0.87 | CES2 (0.48) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7935150 | 0.85 | ALDH1A1 (0.47) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4372774 | 0.84 | HTT (0.55) | ALDH1A1MAPTMEN1KMT2ACES2 | |
| SCHEMBL7978018 | 0.84 | MAPT (0.49) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL7991893 | 0.84 | MAPT (0.53) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105881-B | Platelet aggregation inhibitor, and preparation method and application thereof | 沈阳海诺威医药科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11819503-B2 | Method of treating coccidioides infection | F2G LTD (GB) | 2023-11-21 | — | — | US | disclosed |
| CN-109982704-B | Pharmaceutical preparation | F2G有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-3960734-B1 | PLATELET AGGREGATION INHIBITOR, PREPARATION AND USES THEREOF | SHENYANG HINEWY PHARMACEUTICAL TECH CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| CN-116675704-A | Pyrrole derivative and preparation method and application thereof | 深圳市祥根生物医药有限公司 | 2023-09-01 | — | — | CN | disclosed |
| US-11713300-B2 | Platelet aggregation inhibitor, preparation and uses thereof | SHENYANG HINEWY PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-08-01 | — | — | US | disclosed |
| CN-114644634-B | Pyrrole derivative and preparation method and application thereof | 深圳市祥根生物医药有限公司 | 2023-06-20 | — | — | CN | disclosed |
| CN-111096967-B | Antifungal agent | F2G有限公司 | 2023-03-10 | — | — | CN | disclosed |
| WO-2022134837-A1 | PYRROLE DERIVATIVE, AND PREPARATION METHOD AND USE THEREFOR | 深圳市祥根生物医药有限公司 | 2022-06-30 | — | — | WO | disclosed |
| CN-114105881-A | Platelet aggregation inhibitor and preparation method and application thereof | 沈阳海诺威医药科技有限公司 | 2022-03-01 | — | — | CN | disclosed |
| EP-0587533-B1 | Process for the preparation of alpha-aminoketone salts | CIBA GEIGY AG (CH) | 1997-03-12 | — | — | EP | disclosed |
| EP-0574028-B1 | Dipeptide analogs of aspertame and process to prepare them as well as a new preparation of aspertame | HAMPSHIRE CHEMICAL CORP (US) | 1996-08-28 | — | — | EP | disclosed |
| US-5322964-A | Process for the preparation of alpha-aminoketone salts | CIBA-GEIGY CORPORATION (US) | 1994-06-21 | — | — | US | disclosed |
| EP-0220923-B1 | Dipeptides and process | GRACE W R & CO (US) | 1994-04-27 | — | — | EP | disclosed |
| EP-0587533-A2 | Process for the preparation of alpha-aminoketone salts | CIBA-GEIGY AG (CH) | 1994-03-16 | — | — | EP | disclosed |
| EP-0574028-A1 | Dipeptide analogs of aspertame and process to prepare them as well as a new preparation of aspertame | HAMPSHIRE CHEMICAL CORP. (US) | 1993-12-15 | — | — | EP | disclosed |
| US-4873359-A | Process for preparing as partyl-phenylalanine dipeptides | W. R. GRACE & CO. - CONN. (US) | 1989-10-10 | — | — | US | disclosed |
| US-4810817-A | ARTIFICIAL SWEETENERS | W. R. GRACE & CO. (US) | 1989-03-07 | — | — | US | disclosed |
| US-4710583-A | ENZYMATIC COUPLING OF PHENYLSERINE WITH ASPARTIC ACID; HYDROGENATION | W. R. GRACE & CO. (US) | 1987-12-01 | — | — | US | disclosed |
| EP-0220923-A2 | Dipeptides and process | W.R. Grace & Co.-Conn. (US) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713300-B2 | Platelet aggregation inhibitor, preparation and uses thereof | TFPI, F12, TFPI2 | ALDH1A1 1546/4885MAPT 36/4885SMN1; SMN2 2498/4885 |
| US-11819503-B2 | Method of treating coccidioides infection | DPM1, OAT, OTC | ALDH1A1 415/4885MAPT 3727/4885SMN1; SMN2 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.